XML 74 R62.htm IDEA: XBRL DOCUMENT v3.25.3
Roll-forward of TOI Activity (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 28, 2025
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Dec. 31, 2024
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
R&D Expenses Incurred   $ 2,729,891       $ 2,184,991     $ 7,852,267 $ 5,917,868  
TOI Collaboration Agreement                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Amount Billed/ Submitted for Reimbursement   1,467,935 $ 1,168,022 $ 1,727,386 $ 601,197 1,783,472 $ 1,341,297 $ 189,904     $ 3,915,870
Amount Reimbursed/ Received   (1,422,731) (1,337,604) (990,979) (1,783,472) (1,341,297) (189,904) 0     (3,314,673)
R&D Expenses Incurred   1,657,091 1,682,980 1,969,270 739,557 868,198 1,139,761 189,904     2,937,420
Collaboration Credits   (1,658,248) (1,685,917) (1,966,123) (745,052) (867,760) (1,141,985) (190,553)     (2,945,350)
Variance (foreign exchange timing)   (1,117) (2,937) 3,147 (5,495) 437 (2,223) (649)     (7,930)
Adjustment to Deferred Collaboration Credits   10,015 163,277 251,304 92,546 (788,934) (450,056) 0 424,596 (1,238,990) (1,146,444)
Adjustment to Accrued Expenses   $ 179,141 $ 351,681 (9,420) 45,814 $ (126,340) $ 248,520 $ 0 $ 521,402 $ 122,180 $ 167,994
Phase 3                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Amount Billed/ Submitted for Reimbursement $ 389,782     $ 1,337,604              
Q4 2024 Collaboration Receivable                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Amount Reimbursed/ Received         $ (601,197)